Marina Vainder

Dr. Marina Vainder

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2023 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
MVMarina Vainder
Marina Vainder
JRJoel G. Ray
Joel G. Ray
YLYona Lunsky
Yona Lunsky
KFKinwah Fung
Kinwah Fung
SVSimone Vigod
Simone Vigod
HBHilary K. Brown
Hilary K. Brown

1 September 2019 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
MVMarina Vainder
Marina Vainder
SKSari Kives
Sari Kives
MYMark H. Yudin
Mark H. Yudin

31 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MVMarina Vainder
Marina Vainder
NNNavneet Natt
Navneet Natt
PSParastoo Sayyar
Parastoo Sayyar
ASAmbreen Syeda
Ambreen Syeda
RARizwana Ashraf
Rizwana Ashraf
RDRohan D'Souza
Rohan D'Souza
Objective: To determine whether a third-trimester drop in insulin requirements in pregnant people with pre-existing diabetes is associated with a subsequent occurrence of adverse pregnancy outcomes. Research Design and Methods: We conducted a retrospective cohort study of patients with type 1 and 2 diabetes who were followed at a tertiary referral center in Toronto, Canada. We collected data on insulin dosing in the third trimester (after 28 weeks of pregnancy) and compared outcomes in those with and without a third-trimester drop of 15% or more in their total insulin requirements. Our primary outcome was a composite of stillbirth, spontaneous preterm birth or preterm premature rupture of membranes, and iatrogenic preterm birth or cesarean birth for fetal wellbeing concerns, occurring following the drop in insulin requirements. We conducted regression analyses controlling for early pregnancy glycosylated hemoglobin, body mass index, and diabetes-related microvascular disease, and presented results as odds ratios (OR) with 95% confidence intervals (95%CI). Results: We included 350 pregnant people—146 with type 1 and 204 with type 2 diabetes. Of these, 54 (15.4%) had a third-trimester drop of 15% or more in their total insulin requirements. There was no difference in the primary outcome between groups (OR 0.97; 95% CI 0.41–2.10). Conclusions: Based on this single-center study, limited by sample size and analytic constraints, in people with pre-existing diabetes, a third-trimester drop of ≥15% in total insulin requirements was not associated with subsequent occurrence of adverse pregnancy outcomes. Larger prospective studies looking at associations between a drop in insulin requirements and subsequent occurrence of adverse pregnancy outcomes are necessary to inform meta-analyses and clinical decision making.

22 April 2026 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
MVMarina Vainder
Marina Vainder
ABAnne Berndl
Anne Berndl
APAditi Patrikar
Aditi Patrikar
HBHilary K. Brown
Hilary K. Brown
Objective: To examine the risks of maternal, neonatal and non‐obstetrical medical complications in individuals with cerebral palsy (CP) compared to those without CP. Design: Population‐based cohort study. Setting: Ontario, Canada. Population: Females aged 13–54 years with a livebirth or stillbirth, 2004–2023. Methods: Individuals with ( N = 1400) and without CP ( N = 2 276 561) were compared using modified Poisson regression, adjusted for socio‐demographics, followed by clinical characteristics. Main Outcome Measures: Maternal (e.g., severe maternal morbidity or mortality), neonatal (e.g., severe neonatal morbidity or mortality) and non‐obstetrical medical complications (e.g., seizure disorders) in the perinatal period. Results: After adjusting for socio‐demographics, individuals with CP had an elevated risk, compared to those without CP, of severe maternal morbidity or mortality (adjusted relative risk [aRR] 1.79, 95% confidence interval [CI] 1.36–2.34), caesarean section (1.38, 1.27–1.50) and maternal hospital readmission (1.86; 1.34–2.58). Their newborns were at elevated risk for preterm birth (1.67, 1.43–1.94), small for gestational age (1.34, 1.19–1.52), congenital anomalies (1.77, 1.40–2.24) and severe neonatal morbidity or mortality (1.48, 1.28–1.71). Individuals with CP were also at elevated risk of seizure disorders (13.06, 10.45–16.33) and urinary tract infections (1.50, 1.25–1.79) perinatally. aRRs were slightly attenuated, but remained statistically significant after further adjusting for clinical characteristics. Conclusion: Individuals with CP are at elevated risk of adverse pregnancy outcomes. Findings suggest the need for enhanced preconception counselling, perinatal monitoring and postpartum supports for individuals with CP, facilitated by multidisciplinary care teams.